Detalhe da pesquisa
1.
Characteristics and outcome of immune thrombocytopenia in elderly: results from a single center case-controlled study.
Am J Hematol
; 86(12): 980-4, 2011 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-21956157
2.
Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM).
J Clin Oncol
; 39(14): 1575-1583, 2021 05 10.
Artigo
Inglês
| MEDLINE | ID: mdl-33600210
3.
The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience.
Blood
; 120(25): 5084-5, 2012 Dec 13.
Artigo
Inglês
| MEDLINE | ID: mdl-23243156
4.
Biologics in myelodysplastic syndrome-related systemic inflammatory and autoimmune diseases: French multicenter retrospective study of 29 patients.
Autoimmun Rev
; 16(9): 903-910, 2017 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-28705782
5.
A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML.
Leukemia
; 36(11): 2739-2742, 2022 11.
Artigo
Inglês
| MEDLINE | ID: mdl-36104395
6.
Effect of pregnancy in women with a history of primary immune thrombocytopenia considered as cured.
Eur J Intern Med
; 46: e15-e16, 2017 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-28851549
7.
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.
J Clin Oncol
; 29(24): 3322-7, 2011 Aug 20.
Artigo
Inglês
| MEDLINE | ID: mdl-21788559